Get the Stockscreener App
6.26
2.29%
0.14
Cel-Sci Corp. stock is traded at $6.26, with a volume of 74,733.
It is up +2.29% in the last 24 hours and down -32.03% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$6.12
Open:
$6.09
24h Volume:
74,733
Relative Volume:
0.49
Market Cap:
$50.18M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-12.27
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
-5.44%
1M Performance:
-32.03%
6M Performance:
+38.80%
1Y Performance:
-65.48%
1-Day Range:
$6.00
$6.43
1-Week Range:
$6.00
$6.89
52-Week Range:
$1.98
$32.70
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
6.26 | 48.92M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
Why CEL SCI Corporation stock could see breakout soonShort Setup & Real-Time Volume Analysis Alerts - newser.com
Will Cel Sci Corporation stock profit from AI boomQuarterly Investment Review & Fast Moving Trade Plans - newser.com
Is Cel Sci Corporation stock a buy during volatile marketsInflation Watch & Fast Exit and Entry Strategy Plans - newser.com
Why analysts recommend CEL SCI Corporation (LSR) stockJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
Is CEL SCI Corporation stock attractive for hedge fundsTake Profit & Risk Adjusted Buy and Sell Alerts - newser.com
Is Cel Sci Corporation stock protected from inflation2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
What recovery options are there for CEL SCI CorporationTrade Volume Summary & Growth Focused Stock Reports - newser.com
Will CEL SCI Corporation stock benefit from upcoming earnings reports2025 Top Gainers & Verified Short-Term Trading Plans - newser.com
Can Cel Sci Corporation stock deliver double digit returnsJobs Report & Community Consensus Trade Signals - newser.com
How Cel Sci Corporation stock expands through international marketsQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Why CEL SCI Corporation (LSR) stock is listed among top recommendationsJuly 2025 Highlights & Technical Entry and Exit Alerts - newser.com
Is CEL SCI Corporation (LSR) stock resilient in recession scenarios2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Is Cel Sci Corporation stock prepared for digital transition2025 Big Picture & AI Powered Trade Plan Recommendations - newser.com
How rising interest rates impact CEL SCI Corporation stockMarket Sentiment Summary & Consistent Growth Equity Picks - newser.com
Why Cel Sci Corporation stock is trending on social mediaTrade Entry Report & Weekly Momentum Picks - newser.com
Why CEL SCI Corporation (LSR) stock appeals to dividend investorsBull Run & Consistent Return Strategy Ideas - newser.com
What insider purchases suggest about Cel Sci Corporation stockGap Up & High Yield Stock Recommendations - newser.com
Why Cel Sci Corporation stock is upgraded to buyPortfolio Performance Summary & AI Driven Price Forecasts - newser.com
How CEL SCI Corporation stock reacts to bond yields2025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Is CEL SCI Corporation stock attractive for income investorsExit Point & Intraday High Probability Setup Alerts - newser.com
Key resistance and support levels for CEL SCI CorporationJuly 2025 Short Interest & Weekly Top Performers Watchlists - newser.com
What insider purchases suggest about CEL SCI Corporation (LSR) stockOil Prices & Short-Term High Return Ideas - newser.com
Why CEL SCI Corporation stock is trending among retail traders2025 Market Sentiment & AI Optimized Trade Strategies - newser.com
What analyst consensus implies for CEL SCI Corporation (LSR) stock2025 Technical Patterns & Smart Investment Allocation Insights - newser.com
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):